Journal News

MCP: When prions are personal

Researchers on a quest for a cure publish new assay for monitoring protein level in folding disease
Laurel Oldach
December 01, 2019

Almost everyone produces the prion protein known as PrP, which is found in the brain and cerebrospinal fluid. Like most proteins, PrP folds into a characteristic structure when it is produced. But sometimes that structure can change. When one copy of PrP adopts a misfolded shape, other prion proteins it comes into contact with tend to adopt the same shape. The misfolded proteins spread like an infection, and they tend to clump together, damaging the brain.

Prion protein fibrilsThe prion protein forms fibrils like the ones shown here.NIAID

A research team with an especially personal stake in prion diseases has developed a new measurement that may be useful in testing the treatments they aim to pioneer.

For husband and wife team Sonia Vallabh and Eric Vallabh Minikel, prions became personal when Vallabh’s mother died in her early fifties of a mysterious, rapidly advancing neurodegenerative disease. An autopsy showed that the culprit was a genetic prion disorder, a variant in PrP that makes the protein more likely to adopt a misfolded prion conformation. A test revealed that Vallabh, who is now in her thirties, had the gene too.

“She has a very high probability of developing the same disease by midlife,” Minikel said. “And once it strikes, it’s rapidly fatal.”

After that genetic test, Vallabh and Minikel changed their lives. They started taking night classes in biology and took entry-level jobs in laboratories. They founded the Prion Alliance, a nonprofit dedicated to finding a cure. With support from leaders at Boston’s Broad Institute, they enrolled in Harvard Medical School, and last spring they defended their Ph.D. theses, which focused on the mechanisms of prion disease, in back-to-back seminars. Now they’re looking ahead toward testing treatments.

Researchers hope that if they can find a way to reduce the amount of prion protein in a person predisposed to prion disease, they can reduce the chances that person will develop the disease, or they might be able to delay the onset of symptoms.

But how will researchers know if a potential treatment is working?

“The first and most basic thing you do in a clinical trial that’s the first in humans is you try to find a dose that is potent and tolerated,” Minikel said.

To measure a drug candidate’s potency, researchers usually test for how much it affects its target. In this case, that would mean looking for a drop in PrP after treatment. However, in the normal course of this disease, the amount of detectable PrP drops dramatically after a person begins to show symptoms.

“It’s very nonintuitive … trying to lower a thing that already goes down at the onset of disease,” Minikel said.

If disease progression and an effective drug candidate had the same effect on circulating PrP level, researchers would need to test the drug long before the disease began. And they weren’t even sure if the PrP drop in the test results reflected reality. The most common test relies on an interaction between PrP and an antibody that recognizes its shape. As PrP refolds, the researchers wondered, could it become invisible to the antibody while still present in the cerebrospinal fluid?

As part of his thesis work, Minikel helped develop a new test to resolve this question. With colleagues at the Broad Institute who specialize in proteomics, he came up with a way to detect PrP that doesn’t depend on the protein’s shape. Instead, using a mass spectrometry technique called multiple reaction monitoring, the approach breaks the protein into bits and measures its constituent parts. That means that even if the protein has changed shape, the assay can still detect it. The work recently was published in the journal Molecular & Cellular Proteomics.

Using this new assay to measure biobanked samples from patients, Minikel and his colleagues confirmed that PrP in the cerebrospinal fluid drops in the course of prion disease. Where the PrP goes is still an open question. But with greater confidence that it is indeed dropping when disease starts, the team has a roadmap for the best possible clinical tests for the drugs that they’re starting to develop: They need to test potential drugs in people at risk of prion diseases who have not yet shown symptoms.

Working with a commercial partner, Vallabh and Minikel have started testing drug candidates in mice using antisense oligonucleotides, a technology that should suppress the production of prion protein. They hope it will reduce the damage done by misfolded PrP. The early trials give Minikel hope, he said: Mice with genetic prion disorders, if treated before they show symptoms, survive longer without disease.

Even if this drug candidate doesn’t prove effective, Minikel looks with pride at the groundwork they’ve laid.

“We’ve made tremendous progress in making this a what people in the industry would call a ‘developable disease,’” he said. “And I think that’s a really promising step forward no matter what happens with the antisense oligonucleotides.”

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

A novel technique maps antibodies’ epitope specificities
Journal News

A novel technique maps antibodies’ epitope specificities

January 06, 2021

Determining what proteins an antibody binds can be time and resource intensive. Researchers at Shanghai Jiao Tong University have developed a faster, less expensive approach to epitope mapping.

Cervical Health Awareness Month
Health Observance

Cervical Health Awareness Month

January 04, 2021

Cervical cancer is the most preventable cancer in women, yet more than 300,000 women worldwide lose their lives to it each year.

An immunologist answers three questions about COVID-19
News

An immunologist answers three questions about COVID-19

January 03, 2021

Should pregnant women get the COVID-19 vaccine? Will it protect against asymptomatic infections and mutated viruses?

‘Traffic jam’ discovery in yeast could lead to new disease treatments
Journal News

‘Traffic jam’ discovery in yeast could lead to new disease treatments

January 01, 2021

A Ball State University professor and students have identified two molecules they compare to tow trucks that help keep cells healthy.

New lipid class may shed light on causes of dental disease
Journal News

New lipid class may shed light on causes of dental disease

December 29, 2020

Researchers have made a discovery in mouth bacteria that might be linked via gut microbiota to disorders throughout the body.

From the journals: MCP
Journal News

From the journals: MCP

December 29, 2020

Protein profiles offer new insights into Duchenne muscular dystrophy. A novel fungal protease improves proteomic coverage. Expression of HLA-II shows promise for immunotherapy.